Questcor (QCOR) is a biotechnology company focused on providing prescription drugs for central nervous system disorders. It offers ''Acthar'', the sole revenue driving drug, which treats patients with multiple sclerosis and infantile spasms. Acthar, in the first quarter of 2013, reported $126 million in revenue, compared to the company's total revenue of $135.1 million. This drug accounts to 93% of the total revenue. Its key areas of focus are neurology, nephrology, and rheumatology. The company makes research initiatives on a variety of medical conditions that are not completely controlled or cured with existing drugs on the market.
Acthar will bring additional upside on the revenue
Questcor's Acthar has received FDA approval for 19 separate indications in the...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|